TSPAN4 and neoplasm: Furthermore, gene-editing technologies such as CRISPR/Cas9, or the application of small-molecule inhibitors to disrupt TSPAN4–integrin interactions, may enhance the efficacy of current immunotherapies by overcoming resistance mechanisms and modifying the tumor immune microenvironment (72).